When Curtain Falls: 4+7 To 4+N Signals End To Branded Generics In China?

 
• By Brian Yang

After only two multinationals managed to win bids in China's massive new centralized drug procurement scheme, other foreign firms were hoping to get a break in the second round. But this may not materialize.

Shanghai
EXPANSION OF SHANGHAI-INITIATED '4+7' SCHEME TO BRING PRICE PRESSURE ON BRANDED GENERICS • Source: Shutterstock

More from China

More from Focus On Asia